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the cases, identical TTV strains were present in the biopsy 
and salivary sample of the same HNCC patient. In addition, 
the same TTV strain was detected in 2 laryngeal carcinoma 
biopsies obtained from 2 independent patients.  Conclu-
sions: Our data are compatible with the idea that TTV might 
act as a cocarcinogen in certain cases of HNCC. Alternatively, 
HNCC may facilitate either TTV replication or TTV entry into 
the saliva.  © 2016 S. Karger AG, Basel 
 Introduction 
 Torque teno virus (TTV) is a nonenveloped single-
stranded DNA virus that belongs to the family Anelloviri-
dae. TTV was discovered in the serum of a patient with 
non-A to G hepatitis, an observation suggesting a caus-
ative role for TTV in posttransfusion hepatitis  [1] . Fur-
ther studies showed that TTV is highly prevalent in the 
human population and revealed the broad genetic diver-
sity of the virus  [2, 3] . For this reason, Griffiths  [4] raised 
the point that TTV may establish a commensal relation-
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 Abstract 
 Objectives: Because torque teno virus (TTV) has been impli-
cated in tumorigenesis as a cocarcinogen, we studied TTV 
prevalence in saliva and biopsy samples from head and neck 
cancer (HNCC) patients, patients with premalignant lesions 
of oral cancer, and controls. We also wished to determine the 
TTV genotypes in HNCC patients.  Methods: A seminested 
polymerase chain reaction (PCR) amplifying the N22 region 
of the TTV genome, as well as direct sequencing of PCR frag-
ments, was used.  Results: TTV prevalence was higher in 
HNCC patients (saliva: 27/71, 38%; tumor biopsy: 22/74, 30%) 
than in controls (saliva: 8/56, 14%; oral mucosa: 1/19, 5%). 
TTV prevalence was also high in patients with premalignant 
lesions of oral carcinoma (saliva: 9/18, 50%; biopsy: 5/21, 
24%). By phylogenetic analysis, TTV belonging mostly to 
genotypes 1 and 2 was found in HNCC patients. In most of 
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ship with the infected host. Simmonds et al.  [5] also ar-
gued that TTV might be regarded as ‘‘part of the normal 
human flora’’. Although TTV causes persistent, lifelong 
infection and interacts with various cell types, there is no 
direct proof, as far as we know, of a causative role of TTV 
in human diseases. A higher prevalence or titer of TT vi-
ruses, however, was found to be associated with several 
pathological conditions such as liver and respiratory dis-
eases, hematological disorders, and cancer, including la-
ryngeal and hypopharyngeal carcinoma [reviewed in  3 , 
 6 ]. The exact role of TTV in these pathological conditions 
remains to be established.
 Certain experimental data support the view that TTV 
may induce cell proliferation or have oncogenic proper-
ties  [7] . Yokoyama et al.  [8] observed impairment of renal 
function resembling nephrotic syndrome in transgenic 
mice expressing a spliced transcript from the ORF1 (open 
reading frame 1) gene of TTV. Renal failure was accom-
panied by excessive proliferation and defective differen-
tiation of renal epithelial cells. Yokoyama et al.  [8] specu-
lated that a protein product translated from the spliced 
ORF1 transcript may bind to the cellular DNA and affect 
the pattern of gene expression  [8] . A microRNA encoded 
by the TTV genome may also affect cell proliferation by 
decreasing the response to interferon signaling  [9] . In ad-
dition, Rocchi et al.  [10] observed that cloned DNA of a 
genogroup 4 TTV activated, via TLR9 (toll-like receptor 
9), the expression of inflammatory cytokines in murine 
spleen cells  [10] . An altered cytokine expression may play 
a role in the pathogenesis of head and neck cancer 
(HNCC)  [11] . One may speculate that all of these TTV-
induced changes may facilitate tumorigenesis.
 In contrast, TAIP, a TTV-derived apoptosis-inducing 
protein, may block tumorigenesis or induce programmed 
cell death of carcinoma cells  [12] . The ORF2 protein of 
TTV may also curb tumor development by suppressing 
the production of inflammatory factors activated by NF-
κB  [13] .
 Although the prevalence of TTV in the general popu-
lation is high and it may be regarded as a commensal vi-
rus, certain TTV genotypes may play a role in disease de-
velopment, including carcinogenesis, and it has been
proposed that TTV may act as a cocarcinogen in the 
pathogenesis of laryngeal carcinoma  [14] . For this reason, 
we studied the prevalence of TTV in salivary samples and 
tumor tissues derived from HNCC patients and com-
pared the viral genotypes in their saliva and biopsy sam-
ples. We took advantage of the fact that a high TTV load 
was detected in certain bodily fluids, including saliva, that 
can be collected in a noninvasive way  [3, 15] .
 Materials and Methods 
 Study Design and Collection of Samples 
 The study protocol was approved by the Institutional Review 
Board of the University of Szeged, Szeged, Hungary. Prior to the 
investigation, signed informed consent was obtained from each 
participant enrolled into this study. Saliva and tumor samples of 
HNCC patients and patients with premalignant lesions of oral 
cancer were taken from individuals attending the Department of 
Oto-Rhyno-Laryngology and Head-Neck Surgery, Faculty of 
Medicine, and the Department of Oral Surgery, Faculty of Den-
tistry, University of Szeged, respectively. Unstimulated whole sa-
liva samples were collected via the simple drooling method, ali-
quoted, and stored at –70   °   C until investigation. Samples from 
HNCC lesions and premalignant lesions including oral lichen pla-
nus and leukoplakia were taken by punch biopsy. The tissue sam-
ples were either fixed in formalin and processed for routine histo-
pathologic examination or frozen and stored at –70   °   C until mo-
lecular analysis. Histopathologic diagnosis of the biopsies was 
made at the Department of Pathology, Faculty of Medicine, Uni-
versity of Szeged. Control saliva and in some cases tissue (oral 
mucosa) samples were taken from individuals free of periodonti-
tis, gingival inflammation, and oral mucosal disease who attended 
the Department of Oral Surgery, Faculty of Dentistry, University 
of Szeged. The sources of the samples and the characteristics of 
the patients involved in this study are summarized in  Table 1 . The 
location of head and neck carcinomas is shown in  Table 2 . There 
were 29 pharyngeal and 23 laryngeal squamous cell carcinomas 
and 12 squamous cell carcinomas situated in the oral cavity. One 
lymphoepithelioma was located in the pharynx and 1 laryngeal 
lymphoepithelioma was also recorded. In addition, other tumors 
were also recorded: there were 4 metastases of unknown origin 
located in the lymph nodes of the head and neck region and there 
was 1 maxillary carcinoma and 1 piriform simus cancer. Finally, 
1 maxilloethmoideal neuroendocrine carcinoma was also diag-
nosed ( Table 2 ). Most of the squamous cell carcinomas studied 
were moderately and poorly differentiated or undifferentiated 
(histological grade: G2 to G4) carcinomas belonging to TNM clas-
sification stage III or IV.
 Sample Preparation, Polymerase Chain Reaction, and 
Sequencing 
 Viral DNA was extracted a using Qiagen DNA Mini Kit accord-
ing to the manufacturer’s instructions. Saliva samples were used 
directly in the kit, while tissue samples were ground in mortars 
before nucleic acid isolation. Samples were ground and suspended 
in 400 μL of distilled water, and 200 μL of the suspension was used 
directly in the kit. The presence of TTV was tested by a seminested 
polymerase chain reaction (PCR) performed with primers specific 
for the N22 region of the viral ORF1 (NG063ka CTG GCA TTT 
TAC CAT TTC CAA AGT T, NG059ks ACA GAC AGA GGA 
GAA GGC AAC ATG, and NG061bs GGC ACC ATG YTR TGG 
ATA GAC TGG). The PCR were carried out using REDTaq Ready-
Mix (Sigma) according to the manufacturer’s instructions. The 
PCR conditions for the first PCR were 94  °  C for 3 min, 94  °  C for 30 
s, 55   °   C for 30 s, and 72  °   C for 60 s, with a final extension at 72  °   C 
for 7 min. Thirty-five amplification cycles were performed. The 
conditions for the second reaction were as follows: 94  °  C for 3 min, 
94  °  C for 30 s, 56  °  C for 30 s, and 72  °  C for 60 s, with a final exten-
sion at 72  °  C for 7 min. Twenty-five amplification cycles were per-
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formed. The PCR products were visualized using the GR Safe Nu-
cleic Acid Gel Stain (×10,000 in water) and UV lighting after aga-
rose gel electrophoresis.
 In the case of saliva samples, 2-fold serial dilution of the DNA 
of TTV-positive samples was performed and the same PCR cycles 
were done once again. The most diluted sample that showed posi-
tivity was used in the sequencing reaction; thus, the most abundant 
TTV strain was amplified and could be sequenced directly. In the 
case of tumor samples, this procedure was not necessary as all of 
the tumor samples could be sequenced directly.
 PCR products were purified using the Viogene Advanced TM 
PCR Clean Up System. The purified PCR products were sequenced 
directly from both directions using a ABI BigDye Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems) according to the man-
ufacturer’s protocol. Ethanol precipitation of cycle-sequenced 
products was performed. Cleaned sequenced templates were re-
suspended in Hi-Di formamide (Applied Biosystems) and sepa-
rated and analyzed on an ABI 3500 capillary sequencer. Equivocal 
sequences, mostly resulting from multiple TTV infections, were 
excluded from further analysis. Fourteen TTV samples obtained 
from tumors and 11 from saliva were included in this study, and 
among these there were 11 tumor-saliva sample pairs. The ob-
tained sequences were deposited in GenBank with the accession 
numbers KU720361-KU720375 and KX371259-KX371268.
 Phylogenetic Analysis 
 Manually checked sequences were compared to GenBank da-
tabase entries using the BLAST program. Reference sequences 
were downloaded from GenBank (accession No. AY456101, 
AJ309728, AJ402218, AF060547, AB008394, AB017772, AB017774, 
AB017775, AB017776, AB017777, AB037926, AF261761, 
AB017779, AB054647, AB017778, and AB008394), as well as se-
quences obtained from previous Hungarian studies  [16, 17] (ac-
cession No. FN689754, FN689755, FN689760, FN689770, 
FN689775, FN689782, FN689785, FN689790, FN689791, 
AJ510252, AJ510254, AJ510258, AJ510261, and AJ510262). The 
sequences obtained from patients and reference sequences from 
GenBank were aligned with Multalin. The phylogenetic analyses 
were conducted using  MEGA version 6 via the neighbor-joining 
method and a Kimura 2-parameter nucleotide substitution model 
with bootstrapping of 1,000 repetitions.
 Statistics 
 Statistical analyses were carried out using SPSS v20 software 
with Fisher’s exact test.
 Table 1.  Sample sources and patient characteristics
Head and neck cancer 
patients
Patients with premalignant 
lesions of oral cancer
 Controls
saliva tumor biopsy saliva lesion biopsy s aliva oral mucosa
Samples, n 69a 72 18b 21 58 21c
Mean age of the patients, years 60 59.9 61 62.7 35.8 38.4
Male-to-female ratio 6:1 6:1 1:3 1:3 1:1 1:1
 a Sixty-nine saliva and related tumor biopsy sample pairs. b Eighteen saliva and premalignant biopsy sample 
pairs. c Twenty-one saliva and control oral mucosa sample pairs.
 Table 2.  Location of the head and neck carcinomas analyzed
Tumors at the site, n Note
Tumor location
Pharynx 30 29 HNSCC
1 lymphoepithelioma
Larynx 23 22 HNSCC
1 lymphoepithelioma
Oral cavity 12 12 HNSCC
Other 7 4 lymph node metastases of unknown origin
1 maxillary carcinoma
1 pyriform sinus cancer
1 maxilloethmoideal cancer, neuroendocrine
 HNSCC, head and neck squamous cell carcinoma.
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 Results 
 Using seminested TTV PCR, we found a significantly 
higher TTV prevalence in the salivary samples of HNCC 
patients (27/69; 39%) than in control saliva samples 
(8/56; 14%,  p < 0.005). Similarly, TTV prevalence was 
significantly higher in the tumor biopsy samples of 
HNCC patients (22/72; 30.5%) compared to the available 
oral mucosa samples taken from control patients (1/19; 
5%;  p < 0.03). The TTV prevalence in cases with oral pre-
malignant lesions was also higher in the saliva samples 
(9/18; 50%) compared to the controls ( p < 0.04). The 
TTV prevalence in oral premalignant lesion biopsy sam-
ples (5/21; 23.8%) did not differ, however, significantly 
from that of control oral mucosa samples ( p < 0.18), pos-
sibly due to the relatively low number of samples. The 
TTV prevalence rates are summarized in  Table 3 . Nei-
ther the location of the tumors nor the grade or stage of 
the carcinomas showed a significant correlation with 
TTV prevalence as assessed by seminested PCR (data not 
shown).
 Fourteen TTV strains found in different HNCC biop-
sies and 11 of the related saliva samples were sequenced. 
The biopsy samples were derived from 4 laryngeal squa-
mous cell carcinomas (carrying TTV strains KU720363, 
KU720366, KU720367, and KX371265), 5 pharyngeal 
carcinomas (carrying TTV strains KU720361, KU720368, 
KU720369, KX371264, and KX371267), and 3 oropha-
ryngeal carcinomas (carrying TTV strains KU720364, 
KU720365, and KX371266) ( Fig.  1 ). In addition, there 
was a sample from a sinonasal squamous cell carcinoma 
(carrying TTV strain KU720362) and another derived 
from a neuroendocrine carcinoma located in the max-
illary and ethmoideal sinuses (carrying TTV strain 
KX371268) ( Fig.  1 ). Two of the tumor-associated TTV 
sequences (KU720365 and KU720366) lacked a corre-
sponding salivary sequence pair, and ambiguous TTV se-
quences were found in the salivary sample of a patient 
with a TTV-positive tumor (KU720368); thus, only 11 
salivary TTV sequences were used for phylogenetic anal-
ysis. All of the TTV strains found in the HNCC biopsy 
samples and in saliva samples of HNCC patients belonged 
to genotypes 1, 2, and 3 according to the old classification 
system ( Fig. 1 ). These TTV genotypes were identified ear-
lier in Hungary either in healthy individuals or in differ-
ent patient groups including patients with malignant le-
sions  [16, 17] ( Fig. 1 ). As a matter of fact, in our study the 
majority of the TTV sequences were of genotype 1 or 2; 
only 1 saliva-tumor pair (KU720362 and KU720370) be-
longed to genotype 3. In 9 cases the same TTV strain was 
present both in saliva and in tumor samples; in 2 cases, 
however, different strains were detected. We also noticed 
that the TTV strain detected in the biopsy of a laryngeal 
carcinoma (shown as KU720363 tumor56 LSCC in  Fig. 1 ) 
and in the salivary sample of the same patient (KU720372 
saliva56 LSCC) was identical to the TTV strain detected 
in the tumor biopsy sample derived from another patient 
with laryngeal carcinoma (shown as KU720366 tumor62 
LSCC in  Fig. 1 ). This finding is compatible with the idea 
that certain genogroups, genotypes, or species of the ge-
netically diverse TTV may play a role in the development 
of laryngeal carcinoma.
 Discussion 
 TTV genomes show a high degree of genetic variabil-
ity and they were traditionally divided into 5 phyloge-
netic clusters or genetic groups which show at least
50% nucleotide sequence divergence. Furthermore, each 
group consists of several genotypes separated by more 
than 30% sequence difference from one another [re-
viewed in  3, 18, 19 ]. Hijikata et al.  [20] suggested that the 
high genetic diversity of TTV could possibly be explained 
by a long coevolution of TTV with humans and adapta-
tion of the virus to its host. Although TTV infects a vari-
ety of tissues and cell types, and its cellular receptor re-
mains to be identified, the presence of different viral ge-
notypes in plasma and peripheral blood mononuclear 
cells suggests that TTV variants may preferentially repli-
cate or accumulate in distinct body compartments  [21] . 
In addition, coinfection of the same individual with dif-
ferent TTV genotypes has also been recorded at various 
geographical locations  [16, 18, 21, 22] . Because genetic 
 Table 3.  TTV prevalence in head and neck cancer patients, patients 
with premalignant lesions of oral cancer, and controls
Head and neck cancer patients
Saliva 27/69 (39.1)
Tumor biopsy 22/72 (30.5)
Patients with premalignant lesions of oral cancer
Saliva 9/18 (50)
Lesion biopsy 5/21 (23.8)
Controls
Saliva 8/58 (13.8)
Oral mucosa 1/21 (4.8)
a Values are expressed as the number of TTV-positive samples/
total number of samples with percentages in parentheses.
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KX371262 saliva75 PSCC
KX371267 tumor75 PSCC
FN689782 OSCC
AJ510252 Thun1
KU720374 saliva53 PSCC
KU720361 tumor53 PSCC
FN689785 OSCC
AJ510258 Thun5
AJ402218 Italy plasma
FN689791 OSCC
AY456101 Czech Republic human serum
AJ309728 Poland blood
FN689754 LSCC
AF060547 Germany
TKB212 AB017772 gt2
KU720363 tumor56 LSCC
KU720366 tumor62 LSCC
KU720372 saliva56 LSCC
KU720373 saliva66 OSCC
KU720364 tumor66 OSCC
FN689790 OSCC
KX371260 saliva58 LSCC
KX371265 tumor58 PSCC
AJ510252 Thun2b
KU720367 tumor63 LSCC
FN689755 LSCC
TKB6 AB017774 gt3
KU720370 saliva52 other
KU720362 tumor52 other
TFC3155 AB017777 gt6
THEM1 AB017776 gt5
KX371262 saliva82 other
KX371268 tumor82 other
KU720369 tumor16 PSCC
KU720365 tumor67 PSCC
KU720371 saliva63 LSCC
FN689760 LSCC
TA278 AB008394 gt1
KU720375 saliva16 PSCC
KU720368 tumor17 PSCC
AJ510261 Thun8
KX371259 saliva41 PSCC
KX371264 tumor41 PSCC
FN689770 OL
FN689775 OLP
AJ510262 Thun9
KX371261 saliva29 OSCC
KX371266 tumor29 OSCC
AB017775 gt4
0.1
AB037926 gt14
95
29
29
35
35
37
36
79
99
58
95
100
49
48
4841
99
99
100
100
98
34
65
15
70
99
95
46
43
30
33
75
21
21
15
74
56
51
62
26
63
26
98
18
Gt2
Gt3
Gt1
 Fig. 1. Phylogenetic analysis of TTV strains 
detected in saliva and tumor biopsy sam-
ples of head and neck cancer patients. The 
phylogenetic tree is based on the N22 seg-
ment of the TTV genome and it was con-
structed with Mega6 software using Kimu-
ra’s 2-parameter model. Strains found in 
saliva are indicated by squares, whereas 
strains found in tumor tissues are indicated 
by triangles. Different sequences are indi-
cated by the accession number, the type of 
sample, and a number that refers to the 
code of the patient. Abbreviations refer to 
the location of tumors. LSCC, laryngeal 
squamous cell carcinoma; OSCC, oral 
squamous cell carcinoma; PSCC, pharyn-
geal squamous cell carcinoma; OLP, oral 
lichen planus; OL, oral leukoplakia. ‘‘Oth-
er’’ refers to either a sinonasal squamous 
cell carcinoma (saliva52, tumor52) or a 
neuroendocrine carcinoma located in the 
maxillary and ethmoideal sinuses (sali-
va82, tumor82). Sequences obtained earlier 
in Hungary  [16, 17] are indicated by dia-
monds. Sequences from healthy persons 
 [16] are marked hun after T. A genotype 14 
(gt14) sequence was used as an outgroup to 
root the tree. Numbers on the nodes indi-
cate bootstrap values (%). The rectangle in-
dicates that the same TTV strain was de-
tected in 2 laryngeal carcinoma biopsies 
obtained from 2 independent patients. 
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differences between DNA virus variants may result in dif-
ferent tissue tropisms and an altered pathogenicity  [23, 
24] , one may speculate that certain genogroups, geno-
types, or species of the genetically diverse TTV also play 
a role in disease development  [3] . With respect to HNCC, 
it has been proposed that TTV may act as a cocarcinogen 
in the pathogenesis of laryngeal carcinoma  [14] .
 We found a significantly higher TTV prevalence in sa-
liva (27/71; 38%) and tumor biopsy (22/74; 30%) samples 
of HNCC patients than in control samples (saliva: 8/56, 
13.8%; oral mucosa: 1/19, 5%;  Table 3 ). In addition, we 
found a high TTV prevalence in patients with premalig-
nant lesions predisposing to the development of oral car-
cinoma (saliva: 9/18, 50%; biopsy: 5/21, 24%). We noticed 
that in our study the TTV prevalence in the saliva of con-
trols (13.8%) was comparable with the TTV positivity rate 
of sera derived from healthy individuals (20/108; 18.5%) 
observed in a previous study performed using the same 
seminested PCR assay in Hungary  [16] . Although the 
HNCC patient group and the controls were not age 
matched in the present study, we do not think that age 
had a significant impact on TTV prevalence, because oth-
ers observed no significant difference in TTV prevalence 
between consecutive age groups above 30 years of age 
 [25–27] . Our data suggest that TTV may replicate in cer-
tain HNCC neoplasms and oral precancerous lesions and 
it is transmitted to the saliva of the patients. Alternatively, 
TTV replicating in various cell types of HNCC patients 
may have increased access to the saliva, compared to con-
trol individuals.
 Our phylogenetic analysis showed that the TTV strains 
detected in HNCC patients belonged to genotype 1, 2, or 
3, similarly to the TTV strains identified earlier in healthy 
individuals and various patient groups in Hungary  [14, 
16, 17, 28, 29] ( Fig. 1 ). The TTV genotypes 1, 2, and 3 be-
long to genogroup 1 according to the former classifica-
tion used in most TTV phylogenetic studies, and all of 
them are included in species TTV1 of the novel classifica-
tion system  [17] . Comparison of the TTV sequences in 
saliva/tumor pairs derived from the same individual 
showed that in 9 out of 11 cases the TTV strain detected 
in the tumor biopsy was identical to the one found in the 
salivary sample of the same HNCC patient. In 2 cases, 
however, the sequences differed (samples from a pharyn-
geal carcinoma patient, referred to as KU7202369 tu-
mor16 and KU720376 saliva16 in  Fig.  1 , and samples 
from a laryngeal carcinoma patient, referred to as 
KU720367 tumor63 and KU720371 saliva63 in  Fig.  1 ), 
suggesting the occurrence of mixed infections and pos-
sible compartmentalization of the TTV strains detected.
 Our data revealed that both genotype 1 and genotype 
2 TTV strains could infect both laryngeal carcinomas and 
pharyngeal carcinomas, and they could be detected in the 
saliva of such patients as well. The only genotype 3 TTV 
strain detected was present in the tumor biopsy and sali-
vary sample of a patient with sinonasal squamous cell car-
cinoma (shown as KU720362 tumor52 and KU720370 
saliva52 in  Fig. 1 ). We found, based on sequencing of the 
N22 region of ORF1, that the same TTV strain was pres-
ent in 2 laryngeal carcinoma biopsies obtained from 2 
independent patients (KU720363 tumor56 LSCC and 
KU720366 tumor62 LSCC;  Fig. 1 ). This observation sup-
ports the idea that certain TTV genogroups, genotypes, 
or species may play a role in disease development includ-
ing the development of laryngeal carcinoma  [3, 14] .
 Although several studies have demonstrated the pres-
ence of TTV in saliva, a bodily fluid that can be collected 
in a noninvasive way  [15, 19, 30–33] , the presence and 
genogroup/genotype distribution of TTV in salivary 
samples and in the corresponding tumor biopsies of 
HNCC patients have not been studied before. Our study 
supports the view that the use of saliva samples may con-
tribute to the molecular epidemiological characterization 
of TTV infection and TTV-associated diseases.
 The samples analyzed in our study were collected from 
Southeast Hungary. The distribution of genotypes found 
in this region of the country was similar to those found 
earlier in Hungary  [16, 17] and the Czech Republic, an-
other country in Central Europe  [27] .
 Szládek et al.  [14] noticed that coinfection with geno-
group 1 TTV and HPV was associated with a poor clinical 
outcome of laryngeal carcinoma. A follow-up study dem-
onstrated a high coprevalence of these viruses in lesions 
of oral squamous cell cancer and oral lichen planus com-
pared to healthy mucosa  [29] . Our observation that the 
TTV prevalence was high in patients with lesions associ-
ated with a high risk of oral cancer is compatible with the 
idea that TTV may play a role in oral carcinogenesis. Al-
ternatively, TTV may preferentially target precancerosus 
or inflammatory lesions such as lichen planus and it may 
replicate in such lesions. One may speculate that, in addi-
tion to epithelial cells, T cells could also be potential sites 
of TTV replication  [34] . Further research may elucidate 
the role of TTV in stepwise carcinogenesis.
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